摘要
Background This study aimed to investigate the association between baseline serum tumor markers (STMs) (carcinoembryonic antigen [CEA], neuron-specific enolase [NSE], cytokeratin-19 fragment [CYFRA21-1], carbohydrate antigen 19-9 [CA19-9], and carbohydrate antigen 125 [CA125]) and the efficacy of first-line immunotherapy in patients with advanced non-small cell lung cancer.Methods This multicenter retrospective study evaluated patients who received first-line immunotherapy between July 2017 and July 2022. The endpoints were progression-free survival (PFS) and overall survival (OS), as defined by the Response Evaluation Criteria in Solid Tumors version 1.1. We divided the patients into three groups based on STM levels: Group A =threefold upper limit of normal, threefold upper limit of normal > Group B > upper limit of normal, and Group C =upper limit of normal.Results In total, 716 patients were included in this study. In Cox proportional hazards analyses, the STM levels in Group C were independently associated with superior PFS and OS in patients with lung adenocarcinoma (LUAD). Except for CA19-9 level, the STM levels in Group C were independently associated with superior PFS and OS in patients with lung squamous carcinoma (LUSC). Except for CEA and CA19-9 levels, the levels in Group A were independently associated with inferior PFS and OS in patients with LUAD and LUSC.Conclusions Serum CEA, NSE, CYFRA21-1, and CA125 levels can predict PFS and OS in patients with LUAD and LUSC, and serum CA19-9 levels can predict PFS and OS in patients with LUAD. The higher the serum NSE, CYFRA21-1, and CA125 levels, the worse the PFS and OS in patients with LUAD and LUSC. In addition, the higher the serum CA19-9 level, the worse the OS in patients with LUAD.
学科与关键词
- Dynamic monitoring of serum tumor markers as prognostic factors in patients with advanced non-small-cell lung cancer treated with first-line immunotherapy: a multicenter retrospective studyYang, Xiongwen; Xiao, Yi; Zhou, Yubin; Deng, Huiyin; Yuan, Zihao; Dong, Longyan; Lan, Jun; Hu, Hao*; Huang, Jian*; Huang, Shaohong*Therapeutic Advances in Medical Oncology, 2023, 15: 17588359231206282.
- Peripheral blood markers predict immunotherapeutic efficacy in patients with advanced non-small cell lung cancer: A multicenter studyLiu, Shuai; Zhao, Liuyuan; Zhou, Guohua*Frontiers in Genetics, 2022, 13: 1016085.被引 1
- Baseline C-reactive protein predicts efficacy of the first-line immune checkpoint inhibitors plus chemotherapy in advanced lung squamous cell carcinoma: a retrospective, multicenter studyZheng, Xinlong; Zhang, Longfeng; Wu, Lin; Zhao, Jun; Sun, Jianguo; Fang, Yong; Zhou, Jin; Chu, Qian; Shen, Yihong; Yang, Zhenzhou; Chen, Lijin; Huang, Meijuan; Lin, Xiaoyan; Liu, Zhenhua; Shen, Peng; Wang, Zhijie; Wang, Xin; Wang, Huijuan; Han, Zhengbo; Liu, Anwen; Zhang, Hongmei; Ye, Feng; Gao, Wen; Wu, Fang; Song, Zhengbo; Chen, Shengchi; Zhou, Chenzhi; Wang, Qian; Xu, Chunwei; Huang, Dingzhi; Zheng, Xiaobin; Miao, Qian; Jiang, Kan; Xu, Yiquan; Wu, Shiwen; Wang, Haibo; Zhang, QiuyuBMC CANCER, 2023, 23(1): 1244.
